Minocycline development for acute ischemic stroke - PubMed (original) (raw)

Minocycline development for acute ischemic stroke

Susan C Fagan et al. Transl Stroke Res. 2011.

Abstract

Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood-brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.

PubMed Disclaimer

Figures

Fig. 1

Key milestones in the development of minocycline as an acute treatment for ischemic stroke

Similar articles

• Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline.
  Hess DC, Fagan SC. Hess DC, et al. Rev Neurol Dis. 2010;7 Suppl 1(0 1):S7-13. Rev Neurol Dis. 2010. PMID: 20410869 Free PMC article. Review.
• Minocycline for short-term neuroprotection.
  Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Elewa HF, et al. Pharmacotherapy. 2006 Apr;26(4):515-21. doi: 10.1592/phco.26.4.515. Pharmacotherapy. 2006. PMID: 16553511 Free PMC article. Review.
• Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats.
  Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G, Hess DC. Xu L, et al. BMC Neurol. 2004 Apr 26;4:7. doi: 10.1186/1471-2377-4-7. BMC Neurol. 2004. PMID: 15109399 Free PMC article.
• Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential.
  Machado LS, Sazonova IY, Kozak A, Wiley DC, El-Remessy AB, Ergul A, Hess DC, Waller JL, Fagan SC. Machado LS, et al. Stroke. 2009 Sep;40(9):3028-33. doi: 10.1161/STROKEAHA.109.556852. Epub 2009 Jul 23. Stroke. 2009. PMID: 19628804 Free PMC article.
• Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
  Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Higashida RT, et al. Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17. Stroke. 2003. PMID: 12869717

Cited by

• Anti-inflammatory treatments for stroke: from bench to bedside.
  Drieu A, Levard D, Vivien D, Rubio M. Drieu A, et al. Ther Adv Neurol Disord. 2018 Jul 30;11:1756286418789854. doi: 10.1177/1756286418789854. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 30083232 Free PMC article. Review.
• PeRiodontal Treatment to Eliminate Minority Inequality and Rural Disparities in Stroke (PREMIERS): A Multicenter, Randomized, Controlled Study.
  Redd KT, Phillips ST, McMillian B, Giamberardino L, Hardin J, Glover S, Merchant A, Susin C, Beck JD, Offenbacher S, Sen S. Redd KT, et al. Int J Cerebrovasc Dis Stroke. 2019;2(2):121. Epub 2019 Nov 8. Int J Cerebrovasc Dis Stroke. 2019. PMID: 32159164 Free PMC article.
• Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims.
  Lapchak PA. Lapchak PA. Transl Stroke Res. 2011 Jun 1;2(2):129-35. doi: 10.1007/s12975-011-0074-4. Transl Stroke Res. 2011. PMID: 21666853 Free PMC article. No abstract available.
• Separation Differences Among Phenyl Hydride, UDC Cholesterol and Bidentate C8 Stationary Phases for Stability Indicating Methods of Tetracyclines: Journal of Liquid Chromatography & Related Technologies.
  Young JE, Matyska MT, Azad AK, Yoc SE, Pesek JJ. Young JE, et al. J Liq Chromatogr Relat Technol. 2013 Apr 1;36(7):926-942. doi: 10.1080/10826076.2012.678457. J Liq Chromatogr Relat Technol. 2013. PMID: 24748763 Free PMC article.
• The impact of microglial activation on blood-brain barrier in brain diseases.
  da Fonseca AC, Matias D, Garcia C, Amaral R, Geraldo LH, Freitas C, Lima FR. da Fonseca AC, et al. Front Cell Neurosci. 2014 Nov 3;8:362. doi: 10.3389/fncel.2014.00362. eCollection 2014. Front Cell Neurosci. 2014. PMID: 25404894 Free PMC article. Review.

References

1. 1. Matsukawa N, Yasuhara T, Hara K, Xu L, Maki M, Yu G, et al. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci. 2009;10 (1):126. - PMC - PubMed
2. 1. Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke. 2009;40(11):3580–4. - PubMed
3. 1. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15(6):355–66. - PubMed
4. 1. Coskey R. Acne: treatment with minocycline. Cutis. 1976;17 (4):799–801. - PubMed
5. 1. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med. 1995;122 (2):81–9. - PubMed

Grants and funding

• R01 NS055728/NS/NINDS NIH HHS/United States
• R01 NS055728-02/NS/NINDS NIH HHS/United States
• R01 NS063965/NS/NINDS NIH HHS/United States
• R01 NS063965-03/NS/NINDS NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Springer